Top

Published in:

01-08-2021 | Eclampsia | Letters of Biomedical and Clinical Research

Preeclampsia in primary antiphospholipid syndrome is associated with fetal losses and limb ischemia

Authors: Jozélio Freire de Carvalho, Maria Betania Pereira Toralles, Maria Isabel Figueiredo Sousa, Thelma Larocca Skare

Published in: Clinical Rheumatology | Issue 8/2021

Excerpt

To the editor, …

Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRef

Xi F, Cai Y, Lv M, Jiang Y, Zhou F, Chen Y et al (2020) Anticardiolipin positivity is highly associated with intrauterine growth restriction in women with antiphospholipid syndrome. Clin Appl Thromb Hemost 26:1076029620974455CrossRef

De Carolis S, Tabacco S, Rizzo F, Giannini A, Botta A, Salvi S et al (2018) Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev 17:956–966CrossRef

Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, et al (2016) Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL positive patients: validation of PROMISSE study results. Lupus Sci Med 3:e000131.

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311CrossRef

Wisløff F, Jacobsen EM, Liestøl S (2002) Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 108:263–271CrossRef

Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM et al (2020) Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstet Gynecol S0002-9378:31116–31119

Santiago MB, Paz A (2020) Acute peripheral and/or cutaneous ischemic syndrome: what rheumatologists should know. J Clin Rheumatol. https://doi.org/10.1097/RHU.0000000000001609

Sciascia S, Branch DW, Levy RA, Middeldorp S, Pavord S, Roccatello D et al (2016) The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 115:285–290CrossRef

10.

Mekinian A, Vicaut E, Cohen J, Bornes M, Kayem G, Fain O (2018) Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL clinical trial. Gynecol Obstet Fertil Senol 46:598–604PubMed

11.

Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY (2011) Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf 10:705–714CrossRef

12.

Saavedra MÁ, Miranda-Hernández D, Lara-Mejía A, Sánchez A, Morales S, Cruz-Reyes C et al (2020) Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study. Int J Rheum Dis 235:633–640CrossRef

Title: Preeclampsia in primary antiphospholipid syndrome is associated with fetal losses and limb ischemia
Authors: Jozélio Freire de Carvalho
Maria Betania Pereira Toralles
Maria Isabel Figueiredo Sousa
Thelma Larocca Skare
Publication date: 01-08-2021
Publisher: Springer International Publishing
Keywords: Eclampsia
Antimalaria
Anticoagulant
Antiphospholipid Syndrome
Antiphospholipid Syndrome
Pre-Eclampsia
Published in: Clinical Rheumatology / Issue 8/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05626-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2021

Investigating the relationship between the severity of periodontitis and rheumatoid arthritis: a cross-sectional study

Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease

HLA-subtypes B*27 and ankylosing spondylitis features comments on Fellahi’s article “Are early onset of disease and uveitis affected by HLA- subtypes B*27 in ankylosing spondylitis?”

Correction to: Challenging issues in rheumatology: thoughts and perspectives

Editorial Expression of Concern: Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures

Synovial fluid analysis for the enhanced clinical diagnosis of crystal arthropathies in a tertiary care institution

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

HLA-subtypes B27 and ankylosing spondylitis features comments on Fellahi’s article “Are early onset of disease and uveitis affected by HLA- subtypes B27 in ankylosing spondylitis?”